Which statement about treatment decisions is true?

Boost your readiness for the Primary Open-Angle Glaucoma Test. Utilize flashcards and multiple-choice questions complete with hints and detailed explanations to enhance your understanding.

Multiple Choice

Which statement about treatment decisions is true?

Explanation:
The main idea here is that deciding when to treat open-angle glaucoma is individualized, based on a combination of factors, not just one measurement. Treatment necessity is guided by how advanced the disease is (the extent of optic nerve damage and visual field loss), the level and stability of intraocular pressure, and the presence of risk factors that increase the chance of progression (such as family history, thin corneas, systemic vascular issues, or high peak IOP). Age and overall health or life expectancy also influence how aggressive you should be with therapy, since the benefits and burdens of treatment accumulate over time. In short, the goal is to balance the current disease status with the patient’s overall risk and ability to adhere to treatment, aiming for an individualized target pressure. Basing treatment solely on visible optic nerve damage misses the fact that damage can progress before it’s obvious, and that eyes with high risk factors or fluctuating IOP may need intervention even without clear damage yet. Treating only by IOP elevation ignores the broader risk of progression and the possibility of normal-tension glaucoma. Conversely, treating in every case regardless of stage ignores variability in risk—some eyes have low risk and can be managed with careful monitoring.

The main idea here is that deciding when to treat open-angle glaucoma is individualized, based on a combination of factors, not just one measurement. Treatment necessity is guided by how advanced the disease is (the extent of optic nerve damage and visual field loss), the level and stability of intraocular pressure, and the presence of risk factors that increase the chance of progression (such as family history, thin corneas, systemic vascular issues, or high peak IOP). Age and overall health or life expectancy also influence how aggressive you should be with therapy, since the benefits and burdens of treatment accumulate over time. In short, the goal is to balance the current disease status with the patient’s overall risk and ability to adhere to treatment, aiming for an individualized target pressure.

Basing treatment solely on visible optic nerve damage misses the fact that damage can progress before it’s obvious, and that eyes with high risk factors or fluctuating IOP may need intervention even without clear damage yet. Treating only by IOP elevation ignores the broader risk of progression and the possibility of normal-tension glaucoma. Conversely, treating in every case regardless of stage ignores variability in risk—some eyes have low risk and can be managed with careful monitoring.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy